Literature DB >> 2948032

Lymphadenopathy syndrome in homosexual men. Evidence for continuing risk of developing the acquired immunodeficiency syndrome.

J E Kaplan, T J Spira, D B Fishbein, P F Pinsky, L B Schonberger.   

Abstract

Seventy-five homosexual men with lymphadenopathy syndrome (LAS) for three months or more and antibody against the human immunodeficiency virus were enrolled in a prospective study in Atlanta in 1982 and 1983. Fourteen developed the acquired immunodeficiency syndrome (AIDS) three to 38 months after enrollment in the study and five to 56 months after onset of LAS. The five-year cumulative incidence rate of AIDS after onset of LAS was 29%; yearly incidence rates showed no decreasing trend with time. Of 18 patients with constitutional symptoms and a low T-helper cell count at their first visit, nine developed AIDS; of the remaining 57 patients, five developed AIDS (five-year cumulative incidence rates, 57% and 18%, respectively, P less than .001). Patients with lymphadenopathy syndrome are at continuing risk for the development of AIDS. Those with constitutional symptoms and a low T-helper cell count at their first visit appear to be at higher risk; other LAS patients are at lower risk but may still develop AIDS.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2948032     DOI: 10.1001/jama.257.3.335

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  10 in total

1.  Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques.

Authors:  A M Scharko; S B Perlman; J M Hanson; H Uno; C D Pauza
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 2.  The clinical prognosis of HIV-1 infection: a review of 32 follow-up studies.

Authors:  G S Cooper; D J Jeffers
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

3.  Abnormal antibody responses in patients with persistent generalized lymphadenopathy.

Authors:  H D Ochs; A K Junker; A C Collier; F S Virant; H H Handsfield; R J Wedgwood
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

Review 4.  Immunology of HIV infection and AIDS: memorandum from a WHO/IUIS meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

5.  Quantitative western immunoblotting analysis in survey of human immunodeficiency virus-seropositive patients.

Authors:  D G Schiavini; J M Puel; S A Averous; J A Bazex
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

6.  Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men.

Authors:  P T Schellekens; M T Roos; F De Wolf; J M Lange; F Miedema
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

7.  Deterioration in immunologic status of human immunodeficiency virus (HIV)-infected homosexual men with lymphadenopathy: prognostic implications.

Authors:  T J Spira; J E Kaplan; R C Holman; L H Bozeman; J K Nicholson; D B Fishbein
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

8.  Performance characteristics of an antibody-based multiplex kit for determining recent HIV-1 infection.

Authors:  Kelly A Curtis; Debra L Hanson; Krystin Ambrose Price; S Michele Owen
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

9.  Evaluation of the Abbott ARCHITECT HIV Ag/Ab combo assay for determining recent HIV-1 infection.

Authors:  Kelly A Curtis; Donna L Rudolph; Yi Pan; Kevin Delaney; Kathryn Anastos; Jack DeHovitz; Seble G Kassaye; Carl V Hanson; Audrey L French; Elizabeth Golub; Adaora A Adimora; Igho Ofotokun; Hector Bolivar; Mirjam-Colette Kempf; Philip J Peters; William M Switzer
Journal:  PLoS One       Date:  2021-07-01       Impact factor: 3.240

10.  Evaluation of a multiplex assay for estimation of HIV-1 incidence.

Authors:  Kelly A Curtis; Debra L Hanson; M Susan Kennedy; S Michele Owen
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.